Financial Data and Key Metrics Changes - Total oncology revenue for 2025 was $286 million, including $71 million from R&D-related upfront and milestone revenues [5] - Net income recorded was $457 million, primarily due to a one-time gain from the SHPL divestment of $160 million; core operations remained profitable excluding this gain [5] - R&D expenses decreased to $148 million in 2025, lower than in 2024 due to many late-stage trials nearing completion [6] Business Line Data and Key Metrics Changes - Ex-China sales of FRUZAQLA grew by 26% year-over-year, reaching $366 million in in-market sales [3] - China sales rebounded in the second half of 2025, achieving 21% growth compared to the first half [3] - ORPATHYS and Surufatinib accounted for 11% of total EMARC sales, facing challenges due to competition [10] Market Data and Key Metrics Changes - In the U.S., sales faced headwinds from Medicare Part D redesign, impacting growth [9] - China sales under the brand name ELUNATE experienced a decline of 13% in the first half but rebounded with 33% growth in the second half [9] - The ITP market in China is significant, with over 250,000 actively treated patients, representing a market potential of $500 million to $700 million [19] Company Strategy and Development Direction - The company aims to accelerate global development of its ATTC programs and explore potential in-licensing and M&A opportunities [4][26] - Focus on building a strong hematology portfolio, with the first-in-class treatment for EZH2 mutation approved [11] - The company is pursuing partnerships with multinational companies to validate and add value to its ATTC platform [48] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, with multiple potential NDA filings and expected growth from new hematology products [26] - The oncology revenue guidance for 2026 is projected to be between $330 million and $450 million, reflecting strong growth expectations [7][26] - Management acknowledged the challenges faced in the U.S. market but highlighted the continued expansion of FRUZAQLA in other countries [71] Other Important Information - The company has a strong cash position of approximately $1.4 billion, allowing for accelerated development and exploration of business opportunities [4] - The ATTC platform is designed to reduce toxicities by delivering payloads directly to tumors, targeting a significant market across various cancer types [20][21] Q&A Session Summary Question: Can you elaborate on the oncology guidance for 2026? - Management indicated that the guidance reflects strong momentum and growth from new indications, with expectations for continued recovery [31] Question: What is the status of the SAFFRON readout? - The SAFFRON readout is expected to occur in mid-2026 [32] Question: Can you provide details on the ATTC platform candidates? - The first candidate, HMPL-A251, is currently enrolling HER2-expressing solid tumor patients, focusing on post-HER2 treatment settings [32] Question: How do you expect the changes in Medicare Part D to impact sales? - Management noted that the impact from Medicare changes has already been reflected in 2025 results, but they anticipate continued growth in ex-U.S. markets [71] Question: What is the strategy for partnering with the ATTC program? - The company is open to licensing out some programs to accelerate development while maintaining control over others for long-term value [48] Question: How will the move into hematology products affect sales and marketing investments? - A new business unit with dedicated sales and marketing capabilities has been established to address the hematology market [69]